Working... Menu

TAC Versus TC for Adjuvant Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00493870
Recruitment Status : Active, not recruiting
First Posted : June 28, 2007
Last Update Posted : October 1, 2018
Information provided by (Responsible Party):
US Oncology Research

Brief Summary:
The purpose of this research study is to find out what effects (good and bad) TC or TAC has on early stage HER2- breast cancer.

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: Docetaxel Drug: Doxorubicin Drug: Cyclophosphamide Phase 3

Detailed Description:

Both TAC (docetaxel, doxorubicin, and cyclophosphamide) and TC (docetaxel and cyclophosphamide) are established adjuvant chemotherapy regimens for early stage breast cancer. TAC, however, due to the inclusion of the anthracycline doxorubicin, carries a high risk of hematologic and cardiotoxic adverse effects. Substantial evidence supports the concept that early stage HER2-negative breast cancers will benefit similarly from anthracycline-based adjuvant and non-anthracycline-based chemotherapy.

Further, approximately 0 to 9% of HER2-negative breast cancers have alterations in the TOP2A gene, which may predict for benefit from anthracycline-based chemotherapy.

We hypothesize that 6 cycles of TC versus 6 cycles of TAC will have similar efficacy in the treatment of early stage HER2-negative breast cancer and that TC will have less toxicity. If this hypothesis were upheld and the anthracycline doxorubicin could be eliminated from the regimen while obtaining similar efficacy in this population of patients, it would not only be an important advance in the understanding of the biology of cancer, but it would also be of significant clinical benefit to women with breast cancer.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1296 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Actual Study Start Date : May 29, 2007
Actual Primary Completion Date : May 31, 2015
Estimated Study Completion Date : May 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
Drug Information available for: Docetaxel

Arm Intervention/treatment
Experimental: TC
docetaxel 75 mg/m2 and cyclophosphamide 600 mg/m2
Drug: Docetaxel
Docetaxel 75 mg/m2 IV over 1 hour on Day 1 followed by cyclophosphamide
Other Name: Taxotere

Drug: Cyclophosphamide
600 mg/m2 IV over 15-30 minutes on Day 1.
Other Name: Cytoxan

Active Comparator: TAC
doxorubicin 50 mg/m2, cyclophosphamide 500 mg/m2 and docetaxel 75 mg/m2
Drug: Docetaxel
Docetaxel 75 mg/m2 IV over 1 hour on Day 1 followed by cyclophosphamide
Other Name: Taxotere

Drug: Doxorubicin
• Doxorubicin 50 mg/m2 IV push over 5-15 minutes via sidearm through a running IV line on Day 1, followed by cyclophosphamide 500 mg/m2 IV over 15-30 minutes on Day 1, followed by docetaxel 75 mg/m2 IV over 1 hour on Day 1. Administer pegfilgrastim 6 mg SC on Day 2 (or filgrastim 5 mcg/kg SC per standard of care).
Other Name: Adriamycin

Drug: Cyclophosphamide
600 mg/m2 IV over 15-30 minutes on Day 1.
Other Name: Cytoxan

Primary Outcome Measures :
  1. to compare the 3-year DFS of adjuvant TC versus TAC as treatment for early stage HER2-negative breast cancer. [ Time Frame: 3-year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

A woman will be eligible for inclusion in this study if she meets all of the following criteria:

  • Age >18 to <70 years old.
  • Has known ER and PR status
  • Has HER2 nonamplified disease, confirmed by FISH
  • Has known menopausal status (see Section 7.3 for criteria)
  • Has operable, histologically confirmed, Stage I, IIA, IIB, or IIIA, IIIB, or IIIC invasive carcinoma of the breast. Bilateral synchronous breast cancer is allowable provided that 1 primary meets the inclusion criteria.
  • Meets 1 of the 3 following criteria:

    • T1-3N1-3M0 if ER positive or negative
    • T2-3N0M0 if ER positive or negative
    • T1N0M0 if ER and PR negative
  • Has complete surgical resection of the primary breast tumor: either lumpectomy or mastectomy with sentinel lymph node biopsy or axillary dissection, with clear margins for both invasive and ductal carcinoma in situ (DCIS)
  • Has had no prior chemotherapy unless >5 years ago
  • Has an ECOG Performance Status (PS) 0-1
  • Has laboratory values of: See protocol for specific details
  • Has aspartate aminotransferase (AST) or alanine aminotransferase (ALT) and alkaline phosphatase (ALP) within the ranges shown below. In determining eligibility the more abnormal of the 2 values (AST or ALT) should be used. See protocol for specific details
  • Has normal cardiac function as evidenced by a LVEF >50%, but WNL by institutional standard by multiple gated acquisition (MUGA) scan. An echocardiogram (ECHO) may be used if MUGA is not available, but the same modality must be used consistently throughout the study to evaluate LVEF. Ejection fraction as determined by ECHO must be WNL by institutional standard.
  • Has no evidence of metastatic disease outside of breast by physical examination and chest x-ray. Other scans if done as needed by the patient (eg, bone scan; abdominal, chest CT; PET or PET/CT; ultrasound; or MRI should indicate no evidence of metastatic disease
  • Has had baseline bilateral mammography
  • It has been <84 days since the date of definitive surgery (eg, mastectomy or, in the case of a breast-sparing procedure, axillary dissection) with adequate wound healing, as determined by the Treating Physician
  • Has a negative serum pregnancy test within 7 calendar days prior to registration (female patients of childbearing potential [not surgically sterilized and between menarche and 1 year postmenopause])
  • If fertile, patient has agreed to use an acceptable method of birth control (barrier contraceptive only) to avoid pregnancy for the duration of the study and for a period of 3 months thereafter
  • Has adequate tumor specimen available for FISH analysis of TOP2A status (See Appendix VI).
  • Has signed a Patient Informed Consent Form
  • Has signed a Patient Authorization Form

Exclusion Criteria:

A woman will be excluded from this study if she meets any of the following criteria:

  • Has any evidence of metastatic disease following surgical resection of the primary tumor including: positive surgical margins, staging work-up, or physical examination suspicious for malignant disease
  • Has T4 disease (ie, patients with fixed tumors, peau d'orange skin changes, skin ulcerations, or inflammatory changes)
  • Has Stage IV breast cancer (M1 disease on TNM staging system)
  • Has a history of severe hypersensitivity reaction to drugs formulated with polysorbate 80
  • Has had neoadjuvant chemotherapy for this breast cancer
  • Has ever had a myocardial infarction (MI) or has a history of heart failure, uncontrolled angina, severe uncontrolled arrhythmias, pericardial disease, or electrocardiographic evidence of acute ischemic changes
  • Is receiving concurrent immunotherapy, hormonal therapy (eg, tamoxifen, hormone replacement therapy), or radiation therapy. Must discontinue prior to registering on the study.
  • Is receiving concurrent investigational therapy or has received such therapy within the past 30 calendar days
  • Has peripheral neuropathy >Grade 1
  • Has had a major organ allograft or condition requiring chronic immunosuppression (ie, kidney, liver, lung, heart, bone marrow transplant, or autoimmune diseases). Patients who have received corneal transplants or cadaver skin or bone transplants are eligible.
  • Has a serious uncontrolled intercurrent medical or psychiatric illness, including serious viral (including clinically defined AIDS), bacterial or fungal infection; or history of uncontrolled seizures, or diabetes, or CNS disorders deemed by the Treating Physician to be clinically significant, precluding informed consent
  • Has active hepatitis B or hepatitis C with abnormal liver function tests (LFTs) or is known to be HIV positive
  • Has a history of other malignancy within the last 5 years (except cured basal cell carcinoma of skin, carcinoma in situ of uterine cervix, DCIS, which could affect the diagnosis or assessment of any of the study drugs
  • In an obese patient to whom the Treating Physician would not be comfortable administering full doses of study drugs as calculated by the BSA. Obese patients will be treated based on actual body weight. Obese patients treated with full doses based on actual BSA are eligible.
  • Is pregnant or breastfeeding
  • Is deemed unable to comply with requirements of study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00493870

  Hide Study Locations
Layout table for location information
United States, Alabama
Birmingham Hematology and Oncology
Birmingham, Alabama, United States, 35205
United States, Arizona
Hematology Oncology Associates
Phoenix, Arizona, United States, 85012
Northern AZ Hematology Oncology Associates-AOA
Sedona, Arizona, United States, 86336
Arizona Oncology Associates DBA HOPE
Tucson, Arizona, United States, 85704
United States, California
Central Hematology Oncology Medical Group, Inc.
Alhambra, California, United States, 91801
Comprehensive Blood and Cancer Center
Bakersfield, California, United States, 93309
St. Jude Hertiage Medical Group
Fullerton, California, United States, 92835
Wilshire Oncology Medical Group
La Verne, California, United States, 91750
Antelope Valley Cancer Center
Lancaster, California, United States, 93534
Pacific Shores Medical Group
Long Beach, California, United States, 90813
University of California-Los Angeles
Los Angeles, California, United States, 90095
North Valley Hematology/Oncology Medical Group
Northridge, California, United States, 91325
Ventura County Hematology-Oncology Specialist
Oxnard, California, United States, 93030
Santa Barbara, California, United States, 93105
Santa Barabra Hematology Oncology Medical Group, Inc.
Santa Barbara, California, United States, 93105
Central Coast Medical Oncology Corporation
Santa Maria, California, United States, 93454
United States, Colorado
Rocky Mountain Cancer Center-Rose
Denver, Colorado, United States, 80220
United States, Florida
Flordia Cancer Specialist
Fort Myers, Florida, United States, 33916
Melbourne Internal Medicine Associates
Melbourne, Florida, United States, 32901
Advanced Medical Specialist
Miami, Florida, United States, 33176
Florida Cancer Institute
New Port Richey, Florida, United States, 34655
Ocala Oncology Center
Ocala, Florida, United States, 34474
Cancer Centers of Florida, P.A.
Ocoee, Florida, United States, 34761
United States, Georgia
Suburban Hematology-Oncology Associates, PC
Lawrenceville, Georgia, United States, 30045
Northwest Georgia Oncology Centers, PC
Marietta, Georgia, United States, 30060
United States, Illinois
Hematology Oncology Associates of IL
Chicago, Illinois, United States, 60611
Cancer Care & Hematology Specialists of Chicagoland
Niles, Illinois, United States, 60714
United States, Indiana
Central Indiana Cancer Centers
Indianapolis, Indiana, United States, 46627
Hope Center
Terre Haute, Indiana, United States, 47802
United States, Kansas
Kansas City Cancer Centers-Southwest
Overland Park, Kansas, United States, 66210
United States, Maryland
Maryland Oncology Hematology, P.A.
Columbia, Maryland, United States, 21044
Alliance Hematology Oncology PA
Westminster, Maryland, United States, 21157
United States, Minnesota
Minnesota Oncology Hematology, P.A.
Minneapolis, Minnesota, United States, 554404
United States, Missouri
Missouri Cancer Associates
Columbia, Missouri, United States, 65201
Arch Medical Services, Inc.
Saint Louis, Missouri, United States, 63141
United States, Nevada
Comprehensive Cancer Center of Nevada
Henderson, Nevada, United States, 89052
United States, New Jersey
Hematology-Oncology Associates of NNJ, P.A.
Morristown, New Jersey, United States, 07960
United States, New Mexico
Southern New Mexico Cancer Center
Las Cruces, New Mexico, United States, 88011
New Mexico Cancer Care Associates
Santa Fe, New Mexico, United States, 87505
United States, New York
New York Oncology Hematology, P.C.
Albany, New York, United States, 12206
Interlakes Oncology Hematology, PC
Rochester, New York, United States, 14623
United States, North Carolina
Cancer Centers of North Carolina
Raleigh, North Carolina, United States, 27607
United States, Ohio
Mahoning Valley Hematology Oncology Associates
Boardman, Ohio, United States, 44514
Oncology Hematology Care, Inc.
Cincinnati, Ohio, United States, 45242
Greater Dayton Cancer Center
Kettering, Ohio, United States, 45409
United States, Oregon
Willamette Valley Cancer Center
Eugene, Oregon, United States, 97401
United States, Pennsylvania
Medical Oncology Associates
Kingston, Pennsylvania, United States, 18704
Rittenhouse Hematology/Oncology
Philadelphia, Pennsylvania, United States, 19107
United States, South Carolina
Cancer Centers of the Carolinas
Greenville, South Carolina, United States, 29615
United States, Tennessee
Chattanooga Oncology & Hematology Associates, PC
Chattanooga, Tennessee, United States, 37404
The Sarah Cannon Research Institute
Nashville, Tennessee, United States, 37203
United States, Texas
Texas Cancer Center-Abilene (South)
Abilene, Texas, United States, 79606
Texas Oncology, P.A.-Amarillo
Amarillo, Texas, United States, 79106
Texas Cancer Center
Arlington, Texas, United States, 76014
Texas Oncology Cancer Center
Austin, Texas, United States, 78731
Mamie McFaddin Ward Cancer Center
Beaumont, Texas, United States, 77702
Texas Oncology -Bedford
Bedford, Texas, United States, 76022
Texas Cancer Center at Medical City
Dallas, Texas, United States, 75230
Texas Oncology
Dallas, Texas, United States, 75231
Methodist Charlton Cancer Ctr.
Dallas, Texas, United States, 75237
Texas Oncology
Dallas, Texas, United States, 75246
Texas Cancer Center
Denton, Texas, United States, 76210
El Paso Cancer Treatment Ctr
El Paso, Texas, United States, 79915
Texas Oncology
Fort Worth, Texas, United States, 76104
Texas Oncology
Garland, Texas, United States, 75042
Texas Oncology, P.A.
Houston, Texas, United States, 77024
Lake Vista Cancer Center
Lewisville, Texas, United States, 75067
Longview Cancer Center
Longview, Texas, United States, 75601
South Texas Cancer Center-McAllen
McAllen, Texas, United States, 78503
Texas Cancer Center of Mesquite
Mesquite, Texas, United States, 75150
Allison Cancer Center
Midland, Texas, United States, 79701
Texas Oncology-Odessa
Odessa, Texas, United States, 79761
Paris Regional Cancer Center
Paris, Texas, United States, 75460
South Texas Oncology and Hematology, P.A.
San Antonio, Texas, United States, 78207
San Antonio Tumor and Blood Clinic
San Antonio, Texas, United States, 78217
HOAST-Medical Dr.
San Antonio, Texas, United States, 78229
Texas Cancer Center-Sherman
Sherman, Texas, United States, 75090
Texas Oncology Cancer Center-Sugar Land
Sugar Land, Texas, United States, 77479
Tyler Cancer Center
Tyler, Texas, United States, 75702
Texas Oncology Cancer Care and Research
Waco, Texas, United States, 76712
Texas Oncology PA
Webster, Texas, United States, 77598
Texoma Cancer Center
Wichita Falls, Texas, United States, 76310
United States, Virginia
Fairfax Northern VA Hem-Onc PC
Fairfax, Virginia, United States, 22031
Virginia Oncology Associates
Norfolk, Virginia, United States, 23502
Virginia Cancer Institute
Richmond, Virginia, United States, 23230
Onc and Hem Associates os SW VA, Inc.
Salem, Virginia, United States, 24153
United States, Washington
Highline Medical Oncology
Burien, Washington, United States, 98166
Pudget Sound Cancer Center-Edmonds
Edmonds, Washington, United States, 98026
Columbia Basin Hematology and Oncology
Kennewick, Washington, United States, 99336
Puget Sound Cancer Center-Seattle
Seattle, Washington, United States, 98133
Cancer Care Northwest-South
Spokane, Washington, United States, 99202
Northwest Cancer Specialists-Vancouver
Vancouver, Washington, United States, 98684
Yakima Valley Mem Hosp/North Star Lodge
Yakima, Washington, United States, 98902
Yakima Valley Memorial Hospital/North Star Lodge
Yakima, Washington, United States, 98902
United States, West Virginia
Raleigh Regional Cancer Center
Beckley, West Virginia, United States, 25801
Sponsors and Collaborators
US Oncology Research
Layout table for investigator information
Principal Investigator: Joanne L Blum, MD US Oncology Research

Layout table for additonal information
Responsible Party: US Oncology Research Identifier: NCT00493870     History of Changes
Other Study ID Numbers: 06090
11271 ( Other Identifier: Sanofi-Aventis )
First Posted: June 28, 2007    Key Record Dates
Last Update Posted: October 1, 2018
Last Verified: September 2018

Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Liposomal doxorubicin
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors